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ABSTRACT
Understanding the mechanisms regulating recruitment of human skeletal (stromal or mesenchymal)
stem cells (hMSC) to sites of tissue injury is a prerequisite for their successful use in cell replace-
ment therapy. Chemokine-like protein TAFA2 is a recently discovered neurokine involved in
neuronal cell migration and neurite outgrowth. Here, we demonstrate a possible role for TAFA2 in
regulating recruitment of hMSC to bone fracture sites. TAFA2 increased the in vitro trans-well
migration and motility of hMSC in a dose-dependent fashion and induced signiﬁcant morphological
changes including formation of lamellipodia as revealed by high-content-image analysis at single-cell
level. Mechanistic studies revealed that TAFA2 enhanced hMSC migration through activation of the
Rac1-p38 pathway. In addition, TAFA2 enhanced hMSC proliferation, whereas differentiation of
hMSC toward osteoblast and adipocyte lineages was not altered. in vivo studies demonstrated tran-
sient upregulation of TAFA2 gene expression during the inﬂammatory phase of fracture healing in a
closed femoral fracture model in mice, and a similar pattern was observed in serum levels of TAFA2
in patients after hip fracture. Finally, interleukin-1β was found as an upstream regulator of TAFA2
expression. Our ﬁndings demonstrate that TAFA2 enhances hMSC migration and recruitment and
thus is relevant for regenerative medicine applications. STEM CELLS 2019;37:407–416
SIGNIFICANCE STATEMENT
Skeletal (mesenchymal) stem cells (MSC) are being used in an increasing number of clinical trials
for their therapeutic beneﬁts in tissue regeneration. Understanding the mechanisms that regulate
MSC migration and homing is a prerequisite for their successful use in cell therapy applications.
Results show that TAFA2, a recently identiﬁed neurokine, is highly expressed at the site of skeletal
fracture and induces MSC migration through activation of Rac1/p38 signaling.
INTRODUCTION
Skeletal (also known as bone marrow stromal
or mesenchymal) stem cells (MSC) are nonhe-
matopoietic cells residing in the bone marrow
stroma and are capable of differentiation to
mesodermal cell types such as osteoblasts, adi-
pocytes, and chondrocytes [1, 2]. MSC are
recruited to the bone formation sites during
bone remodeling and after bone fracture,
where they differentiate into osteoblastic
bone-forming cells [3]. Insufﬁcient or defective
recruitment of MSC to bone formation sites
has been suggested as a mechanism mediating
impaired bone formation in osteoporosis and
in nonunion or poorly healing fractures [4, 5].
MSC are being tested in an increasing
number of clinical trials for enhancing tissue
regeneration, including bone tissue regeneration,
where direct transplantation of MSC cultured on
scaffolds has been tested with good preliminary
results [6–8]. Systemic (intravenous) infusion of
MSC is an attractive route of administration
because of its ease and clinical feasibility [6–8].
Also hematopoietic stem cell (HSC) transplanta-
tion has demonstrated the ability of HSC to
home to their bone marrow niche after intrave-
nous infusion and to exert their biological func-
tions [9], suggesting that MSC may be equipped
with similar functional capacity.
Previous studies have demonstrated the
presence of MSC in the circulation and that
they can be recruited to injured tissues (for
review, please see [10]). MSC can adhere to
endothelial cells and exhibit leukocyte-like
trans-endothelial migration [11]. However, few
cells are recruited to fracture sites after sys-
temic infusion of MSC [12, 13]. Interestingly,
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some studies have reported enhanced tissue regeneration
despite the presence of few engrafted MSC [14–17]. To
increase the number of MSC homed to the bone, a number of
approaches have been tried, for example, modifying CD44
expression by MSC [18] or surface conjugation of MSC with a
synthetic peptidomimetic ligand with high afﬁnity for activated
α4β1 integrin to target MSC to the skeleton [19] or to precon-
dition MSC with small molecules before systemic infusion in
order to boost their skeletal homing properties [12].
In order to identify secreted factors with capacity for enhanc-
ing recruitment of MSC to the skeleton, we examined a number of
factors known to regulate migration and motility of adult stem
cells in a number of tissues. We identiﬁed TAFA2 in a screening
experiment using chemoattraction of MSC as an endpoint. TAFA2
(also known as FAM19A2, family with sequence similarity 19 mem-
ber A2) is a member of FAM19A family consisting of ﬁve highly
homologous genes (TAFA1-5) encoding small secreted proteins
[20]. TAFA proteins are broadly expressed with highest expression
in the brain and function as neurokines [20]. Despite lack of func-
tional studies about biological roles of TAFA2, genome-wide associ-
ation studies have revealed an association between TAFA2 gene
polymorphism and mental retardation and insulin sensitivity
[21, 22]. Here, we report a novel role for TAFA2 in recruiting
human MSC (hMSC) to the site of skeletal fracture. Using cell-
based and in vivo studies, we show that TAFA2 stimulates hMSC
migration through activation of Rac1-p38 signaling. TAFA2 overex-
pression at the site of skeletal fracture increased the number of
recruited hMSC to the injured tissue. TAFA2 levels were differen-
tially regulated during the time course of fracture healing in a
closed femoral fracture model in mice, and a similar pattern was
observed in TAFA2 serum levels in patients with hip fractures.
MATERIALS AND METHODS
MSC Culture
As a model for primary hMSC, we used our well-characterized,
immortalized human MSC line (hereafter referred to as hMSC),
established by ectopic expression of the catalytic subunit of
human telomerase as previously described [40]. hMSC main-
tain all typical characteristics of primary hMSC [41]. Primary
bone marrow-derived hMSC (hereafter referred to as hpMSC)
were established from fresh bone marrow aspirates as previ-
ously described, from three young healthy donors after
informed consent [42]. The cells were cultured in a standard
growth medium containing minimal essential medium (MEM;
Gibco, Invitrogen, Grand Island, NY) supplemented with 10%
fetal bovine serum (FBS; Biochrom, Germany) and 1% penicil-
lin/streptomycin (Gibco, UK) at 37C in a humidiﬁed atmo-
sphere containing 5% CO2. The medium was changed every
third day until the cells became 90% conﬂuent.
Boyden Chamber Chemotaxis Trans-Well Migration
Assay
The migration ability of hMSC toward a number of chemoat-
tractant factors identiﬁed by NeuroSearch A/S, Copenhagen,
Denmark, and provided by Dr. Per Horn was measured in a
48-well microchemotaxis Boyden chamber-based cell migration
assay (8 μm pores, polycarbonate membrane, NeuroProbe,
Inc., USA). The membrane was coated for 1 hour at 37C with
migration media (low glucose Dulbecco’s MEM [LG-DMEM,
Gibco]), supplemented with 0.2% FBS (Gibco) containing
5 μg/ml ﬁbronectin and 10 μg/ml rat tail collagen I. hMSC were
serum starved in migration media 24 hours before migration
assay. The chemotaxis and control media (27 μl) were placed in
the lower chamber and covered by the coated membrane and
ﬁxed by the upper chamber. hMSC (1.25 × 104) suspended in
50 μl migration media were loaded into each well of the upper
chamber. The migration was carried out for 4 hours in 37C.
Nonmigrated cells on the upper side of the membrane were
scraped and rinsed with cold phosphate buffered saline (PBS).
Migrated cells on the lower side of the membrane were ﬁxed
and stained with hemacolor staining kit (Merck, Germany).
The migrated cells were scanned and photos were taken at
×20 magniﬁcation by a computer-assisted cell-counting system
(Visiopharm, Denmark). Images were captured of the entire
wells and counted by using ImagJ software. Results were
expressed as mean number of cells per at least six replicates
and three independent experiments. For inhibition of the sig-
naling pathways, the cells were incubated 30 minutes before
the seeding in the chambers, with p38 inhibitor SB203580
(Sigma) or dimethyl sulfoxide (DMSO) (Sigma, USA) used as
vehicle.
Oris Cell Motility Assay
The assay was performed according to the manufacturer’s
instructions (Platypus, Madison, WI). Brieﬂy, 96-well cell culture
plates were coated with ﬁbronectin (10 μg/ml) in PBS for 2 hours
at 37C, rinsed twice with PBS. After washing, the Oris cell seed-
ing stoppers were inserted in the wells. hMSC were trypsinized,
washed twice with MEM, and resuspended in 0.2% serum
medium, seeded and permitted to attach at a density of
2.5 × 103 cells in each well. Thereafter, the stoppers were gen-
tly lifted from all wells excluding the designated “reference”
wells (n = 6). Then, cells were washed with migration media
(LG-DMEM, supplemented with 0.2% FBS) and permitted to
migrate during 24 hours in fresh migration media supplemented
with chemoattractant in a humidiﬁed chamber (37C, 5% CO2).
The cells were washed and ﬁxed for 10 minutes in 4% parafor-
maldehyde/PBS, permeabilized with 0.1% Triton X-100 in PBS
and stained with tetramethylrhodamine (TRITC)-conjugated phal-
loidin solution for 40 minutes followed by 40,6-diamidino-
2-phenylindole (DAPI; 1 μg/ml). The mean ﬂuorescence intensity
of the migrated cells was analyzed by an enzyme-linked immu-
nosorbent assay (ELISA) microtiter plate reader (FLUOstar
Omega, BMG LABTECH, Ortenberg, Germany).
Quantitation of Cell Spreading and Immunoﬂuorescent
Intensity
Ninety-six-well cell culture plates (Perkin Elmer, Denmark) were
coated with ﬁbronectin (10 μg/ml) in PBS for 2 hours at 37C,
rinsed twice with PBS, and blocked with 1% BSA for 1 hour. hMSC
were trypsinized, washed twice with MEM media, and resus-
pended in serum-free medium. Cells were stimulated with
10 μg/ml TAFA2 (R&D systems, Minneapolis, MN) for 30 minutes
at 37C and then replated onto ﬁbronectin-coated plates in stan-
dard culture medium. Cells were ﬁxed in 4% paraformaldehyde for
10 minutes, washed with PBS, and stained for F-actin with phalloi-
din (TRITC-labeled, Sigma) and DAPI for nuclear staining.
Fluorescent images were analyzed by Operetta high-content-
imaging system (Perkin Elmer) at ×20 magniﬁcation using Harmony
High Content Imaging and Analysis Software (PerkinElmer).
©2018 The Authors. STEM CELLS published by
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Western Blotting Analysis
hMSC were cultured until 80% conﬂuent, then starved in migra-
tion media for 24 hours before treatment with TAFA2 at
10 μg/ml or 10% FBS. Protein samples were harvested at 0, 10,
30, 60, 120, and 240 minutes after treatment. Brieﬂy, cells were
washed in PBS and lysed in RIPA buffer (Sigma, USA) supple-
mented with protease and phosphatase inhibitors (Roche,
Germany). After 30 minutes incubation at 4C, samples were
centrifuged for 10 minutes at 12,000 rpm, 4C. Protein concen-
tration was determined with Pierce Coomassie Plus Bradford
assay (Thermo Fisher Scientiﬁc, USA), and equal amounts of
proteins were loaded on a 10% polyacrylamide gel (Novex, Life
technologies, USA). Blotted nitrocellulose membranes were
incubated overnight with antibodies against P-p38, p38, P-AKT,
AKT, P-ERK, ERK2 (Cell Signaling, USA), and α-tubulin (Sigma,
USA), overnight at 4C. Membranes were incubated with horse-
radish peroxidase (HRP)-conjugated secondary antibody (Santa
Cruz Biotechnology, USA) for 45 minutes at room temperature,
and protein bands were visualized with Amersham ECL chemi-
luminescence detection system (GE Healthcare, UK).
In Vivo Studies of Fracture Healing
The ethical approval for femur fracture in mice was granted
by the Danish National Animal Experiment Inspectorate (2012-
15-2934-00559). Female immunodeﬁcient NOD.CB17-Prkdcscid/J
(NOD-scid, 12 weeks old) and C57BL/6J (10 weeks old) mice
were anesthetized by administration of intraperitoneal ketamine
hydrochloride (100 mg/kg body weight) and xylazine hydrochlo-
ride (10 mg/kg). The closed femur fracture procedure was car-
ried out as described [45]. Brieﬂy, an incision was made just
medial to the patella, and the fracture was ﬁxed by inserting a
0.5 mm needle between the condyles and drilled in a retrograde
fashion into the medullary cavity of the femur. Afterward, a stan-
dardized reproducible closed fracture was induced using a blunt-
impact guillotine fracture apparatus. A radiograph was acquired
after fracture induction (using Faxitron MX-20; Faxitron, USA) to
conﬁrm the fracture induction and needle position.
Immunohistochemical Staining
Tissues were harvested at different time points and ﬁxed in 4%
formalin for 3 days. Bones were decalciﬁed in formic acid. The
tissue was parafﬁn embedded, sectioned, and stained for human
TAFA2 protein expression. Brieﬂy, the staining was performed
using DAKO En Vision+ and PowerVision according to manufac-
turer’s instructions. The tissue sections were demasked using
TEG solution (Tris 10 mM, EGTA 0.5 mM, pH 9.0) (15 minutes)
and incubated 1 hour with sheep anti-human TAFA2 antibodies
(R&D Systems, Abingdon, U.K.) diluted in ChemMate Antibody
diluent (1:30 Dako, Glostrup, Denmark). After washing, the sec-
tions were incubated with secondary antibody (rabbit anti-goat
antibody, cell signaling, USA) for 20 minutes. The slides were
processed on an automatic slide processor (Techmate500, Dako,
Glostrup, Denmark). Analysis was carried out on an IX50 Olym-
pus microscope using Olympus DP Software v3.1 (Olympus,
Essex, U.K.) or a Leica DM4500 (Leica, Wetzlar, Germany) using
the Surveyor Turboscan Mosaic acquisition imaging analysis sys-
tem v5.04.01 (Objective Imaging Ltd, Cambridge, U.K.).
Antibody Labeling and Flow Cytometry Analysis
The cells were incubated with antibodies against cell surface
proteins for 20 minutes on ice, and two washes with PBE (PBS
containing 2 mM EDTA and 0.5% FBS) were done to remove
unbound antibody. For intracellular staining of TAFA2, the cells
were ﬁxed and permeabilized with BD-ﬁxation and permeabili-
zation kit (BD Biosciences, USA), and the cells were stained
with 2 μg anti-TAFA2 antibodies and incubated for 1 hour on
ice in dark. Cells were washed, ﬁxed in 2% paraformaldehyde,
and cell acquisition was performed with ﬂow cytometer BD
FACS LSRII. Kaluza 1.2 software program was used for analysis
of the data. Mean ﬂuorescence intensity (MFI) value of a rele-
vant isotype control staining was subtracted from the corre-
sponding MFI of the speciﬁc staining. The ﬂow cytometer was
standardized by using positive and negative controls and ﬂow
check beads each time to reduce day-to-day variation.
RNA Extraction and Quantitative Reverse Transcription
Polymerase Chain Reaction
RNA was isolated from organs or cultured cells according to
previously published method. [43] After cDNA synthesis, quan-
titative reverse transcription polymerase chain reaction was
performed using a comparative Ct method [(1/ (2ΔCt)] formula,
and data were represented as relative expression to the HPRT1
reference gene.
Osteoblast Differentiation and ALP Activity Assay
Osteogenic induction was performed using MEM supplemented
with 10 mM β-glycerophosphate (Calbiochem-Merck, Germany),
50 μg/ml L-ascorbic acid-2-phosphate (Wako Chemicals GmbH,
Germany), 10 nM dexamethasone (Sigma-Aldrich, Denmark),
and 10 nM calcitriol (1.25-dihydroxy vitamin-D3) kindly provided
by Leo Pharma, Ballerup, Denmark. Medium was changed every
third day during induction. The induction was performed with
and without addition of different concentrations of rhTAFA2
protein. ALP activity was measured at day 6 of induction. Simul-
taneously, the numbers of viable cells were determined on the
day of ALP activity measurement by adding the CellTiter-Blue
solution (Promega, USA) to the wells. The cells were then rinsed
with TBS (20 mM Trizma base, 150 mM NaCl at pH = 7.5)
and ﬁxed in 3.7% formaldehyde-90% ethanol for 30 seconds
at room temperature. A reaction mixture containing 100 μl
50 mM NaHCO3, 1 mM MgCl2 (Sigma, USA), and 1 mg/ml of
p-nitrophenyl phosphate (Sigma) was added into each well and
incubated 20 minutes at 37C. The reaction was stopped by
adding 50 μl of 3 M NaOH. The absorbance at 405 nm was
determined using an ELISA microtiter plate reader (FLUOstar
Omega, BMG LABTECH, Ortenberg, Germany). ALP enzymatic
activity was normalized to the number of viable cells. After
osteoblastic induction at day 15, assessment of hydroxyapatite
deposition was performed using the OsteoImage Bone Minerali-
zation Assay (Lonza, USA) according to manufacturer’s instruc-
tions. Data were analyzed, and noninduced cells were compared
with induced and induced cells supplemented with rhTAFA2
(10 μg/ml).
Adipogenic Differentiation
Adipogenic differentiation of hMSC was induced using MEM
supplemented with 10% FBS (Sigma-Aldrich, Brøndby, Denmark),
10% horse serum (Sigma-Aldrich, USA), 100 nM dexamethasone
www.StemCells.com ©2018 The Authors. STEM CELLS published by
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(Sigma-Aldrich, Denmark), 500 μM 1-methyl-3-isobutylxanthine
(IBMX, Sigma-Aldrich, USA), 1 μM rosiglitazone (BRL49653,
Cayman Chemical, Ann Arbor, MI), and 5 μg/ml insulin (Sigma-
Aldrich, USA) for 15 days. Media was changed every third day,
and rhTAFA2 (10 μg/ml) was added to induced cells. Oil Red O
staining and quantiﬁcation was performed as previously
described [43].
siRNA Transfection
siRNA transfection was performed using a reverse transfection
protocol as previously described [42]. Brieﬂy, Lipofectamine
2000 was used as transfection reagent, and transfections were
carried out according to the manufacturer’s instructions
(Invitrogen, USA). Nontargeting siRNA No.2 (Ambion, CA, USA)
and siRNA against Rac1 (sense: CUACUGUCUUUGACAAUUAtt)
(Ambion) were used at 25 nM.
ELISA Measurement of TAFA2 Concentrations in
Clinical Samples
ELISA measurements of TAFA2 concentrations in human serum
samples were performed using an established ELISA procedure
(Mybiosource, San Diego, USA) according to the manufac-
turer’s instructions. The human serum samples used in this
study were from patients with traumatic hip fracture admitted
to the Orthopaedic Department at Herlev Hospital. The experi-
mental protocol was approved by the regional scientiﬁc ethical
committee in Copenhagen (Number KA 05081). All patients
received oral and written information and participated under
signed informed consent. Collection and handling of the serum
samples was previously published [44].
RESULTS
TAFA2 Enhanced Migration and Motility of hMSC
To identify novel regulators of hMSC recruitment to injured tis-
sues, we screened a number of newly identiﬁed chemoattractant
neurokines, for their ability to enhance in vitro trans-well migra-
tion of hMSC using a three-dimensional-Boyden chamber assay.
The members of TAFA family, TAFA2, 4, and 5, exhibited the high-
est chemoattractant activity for hMSC (Fig. 1A). Next, we used
the Oris assay to conﬁrm the trans-well migration-stimulating
activity of TAFA proteins and found that TAFA2 is the most potent
stimulator of hMSC motility (Fig. 1B, 1C). TAFA2 also stimulated
cell motility in cultures of human primary bone marrow-derived
MSC (hpMSC; Fig. 1D). To specify whether TAFA2-induced cell
migration is directional (chemotaxis) or random (chemokinesis),
TAFA2 was added to both upper and lower compartments of the
Boyden chamber and we observed a signiﬁcant reduction in num-
ber of migrating hMSC (Fig. 1E) and hpMSC (Fig. 1F). TAFA2 exhib-
ited a dose-dependent chemoattractant effect on the trans-well
migration of hMSC (Fig. 1G), and a similar effect was observed in
hpMSC (Fig. 1H, 1I). In addition, combining TAFA2 with different
concentrations of anti-human TAFA2 antibody reduced the che-
motactic activity of TAFA2 (Fig. 1J).
TAFA2 Stimulates hMSC Migration Through Activation
of Rac1-p38 Signaling
Formation of lamellipodia is an early event initiating migration of
various cell types such as ﬁbroblasts and leukocytes [23]. We
used the Operetta high-content-imaging system to perform
quantitative analysis of TAFA2-induced morphological changes in
cultured hMSC at a single-cell resolution. We noted that TAFA2
induced formation of lamellipodia (cell protrusions that are
needed for cell movement) in cultured hMSC (Fig. 2A) that was
associated with increased cell area (Fig. 2B). We then examined
the activation status of Rac1 GTPase that is required for forma-
tion of lamellipodia and cell migration. Analysis of lysates from
TAFA2-stimulated hMSC showed signiﬁcantly increased levels of
Rac1 activity at 10, 15, and 30 minutes after TAFA2 stimulation,
which returned to the initial levels after 60 minutes (Fig. 2C). To
examine the role of Rac1 in TAFA2-induced hMSC migration, we
performed small interfering RNA (siRNA)-mediated knockdown of
Rac1, which decreased Rac1 expression in hMSC cultures
(Fig. 2D) and abolished the TAFA2-induced hMSC trans-well
migration (Fig. 2E). To identify the downstream signaling path-
ways involved in TAFA2-mediated hMSC motility, we examined
the activation status of several signaling factors involved in cell
migration: p38, AKT, and ERK. We found increased levels of P-
p38 within the initial 2 hours after TAFA2 stimulation (Fig. 2F;
Supporting Information Fig. S1). We did not detect changes in
P-Akt and P-ERK levels in TAFA2-stimulated hMSC cultures
(Fig. 2F). Interestingly, inhibition of p38 signaling using SB203580
abolished TAFA2-induced hMSC migration in a dose-dependent
manner (Fig. 2G, 2H).
TAFA2 Regulates Proliferation, but Not Differentiation
of hMSC
To investigate other possible functions of TAFA2 in hMSC biol-
ogy, we tested whether TAFA2 could exert a regulatory effect
on hMSC proliferation or differentiation. Adding TAFA2 to
hMSC cultures in the presence of normal culture media
increased cell proliferation as shown by increased cell number
and Ki67 levels (Fig. 3A, 3B). Next, we examined TAFA2 expres-
sion during ex vivo differentiation of hMSC toward osteoblastic
and adipocytic lineages. TAFA2 mRNA expression increased
during osteoblast and adipocyte differentiation of hMSC
(Fig. 3C, 3D). However, TAFA2 did not affect osteoblast differ-
entiation as shown by quantitation of alkaline phosphatase
(ALP) activity (Fig. 3E, 3F) and mineralized matrix formation
assessed by measuring deposition of hydroxyapatite (Fig. 3G, 3H).
Similarly, TAFA2 did not affect adipocyte differentiation of
hMSC evidenced by measuring the number of mature lipid-
ﬁlled adipocytes (Fig. 3I, 3J).
TAFA2 Levels Are Differentially Regulated During
Fracture Healing
To determine the relevance of TAFA2 to pathophysiology of
fracture healing, we examined the pattern of TAFA2 expression
at different phases of fracture healing in the mouse femoral
fracture model. TAFA2 was highly expressed at the site of frac-
ture 48 hours post induction. TAFA2 immunoreactivity was
present in the fracture line-adjacent bone marrow and in the
injured muscle tissue above the fracture line, where the blunt
impact from a dropped weight induced the mid-diaphysis frac-
ture (Fig. 4A). Interestingly, TAFA2 protein expression was
already increased 2 hours after the fracture and expression
peaked during the ﬁrst week of fracture (Fig. 4B). TAFA2
mRNA and protein expression was also differentially regulated,
with an initial increase in the early phase of fracture healing
followed by downregulation (Fig. 4C, 4D). A similar pattern of
expression was observed for the pro-inﬂammatory cytokine
©2018 The Authors. STEM CELLS published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press 2018
STEM CELLS
410 TAFA2 Induces Skeletal Stem Cell Migration
interleukin-1β (IL-1β) (Fig. 4E). To investigate the role of IL-1β
as an upstream regulator of TAFA2 expression, we added differ-
ent doses of IL-1β to hMSC cultures and observed an enhancing
effect on TAFA2 mRNA and protein levels (Fig. 4F, 4H).
We then determined the cellular map of TAFA2 expression
within the bone marrow during fracture healing. Interestingly,
intracellular expression of TAFA2 in different leukocyte sub-
populations was detectable with high levels of TAFA2 expres-
sion in monocytes and T cells at day 1 postfracture that was
downregulated by day 3 (Fig. 4I), while monocyte cell fre-
quency was not altered, and T-cell frequency was increased
on day 3 postfracture compared to day 1 (Fig. 4J). To extrapo-
late these ﬁndings to human physiology, we assessed the
kinetics of TAFA2 levels in consecutive serum samples from
patients after hip fracture. TAFA2 serum levels were high at
the ﬁrst day after hip fracture and decreased gradually in the
subsequent measurements during a 21 day observation period
(Fig. 4K).
DISCUSSION
In the present study, we identiﬁed the neurokine TAFA2 as a
novel chemoattractant factor for hMSC that is expressed during
the inﬂammatory phase of bone fracture healing and enhances
in vitro transmigration of hMSC. Because of the limited number
of factors known to exert speciﬁc effects on MSC migration
and recruitment capacity, studying the role of TAFA2 in MSC
Figure 1. TAFA2-enhanced migration of human skeletal (stromal, mesenchymal stem) cells (hMSC). (A): Screening of a number of
secreted neurokines (25 μg/ml) for chemotactic activity in hMSC cultures using an in vitro three-dimensional-Boyden chamber trans-well
migration assay. Data represent mean  SEM from six independent experiments. **, p ≤ .01, two-tailed unpaired Student t test.
(B, C): Measuring two-dimensional (2D) migration of hMSC in the presence of TAFA2, TAFA4, and TAFA5 (10 μg/ml) using Oris cell migra-
tion assay. Scale bar: 50 μm. Data represent mean  SEM from three independent experiments. *, p ≤ .05; **, p ≤ .01, two-tailed unpaired
Student t test. (D): 2D migration of primary hMSC (hpMSC) in the presence of TAFA2 (10 μg/ml) using Oris cell migration assay. Scale bar:
50 μm. Data represent three independent experiments. Quantitation of trans-well migration of hMSC (E) and hpMSC (F) in the presence of
recombinant human TAFA2 (10 μg/ml) in different compartments of Boyden chamber assay, LC and UC. Data represent mean  SEM from
three independent experiments **, p ≤ .01, two-tailed unpaired Student t test. Quantitation of trans-well migration of hMSC (G) and
hpMSC (H) in the presence of different doses of TAFA2 (10 ng/ml, 100 ng/ml, 1 μg/ml, and 10 μg/ml). Data represent mean  SEM from
three independent experiments. *, p ≤ .05; **, p ≤ .01, two-tailed unpaired Student t test. (I): Hemacolor staining of migrated cells toward
different concentrations of TAFA2 (10 ng/ml, 100 ng/ml, 1 μg/ml, and 10 μg/ml) was present in the lower compartment of the Boyden
chamber. Scale bar: 50 μm. Data are representative of three independent experiments. (J): Measuring hMSC trans-well migration in the
presence of TAFA2 (10 μg/ml) with and without anti-human TAFA2 antibody (2.5 and 5 μg/ml). Data represent mean  SEM from three
independent experiments. **, p ≤ .01, two-tailed unpaired Student t test. Abbreviations: LC, lower chamber; UC, upper chamber.
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biology is relevant for better understanding the biological pro-
cesses of bone remodeling and fracture healing as well as pos-
sible use for enhancing MSC recruitment to injured sites in
regenerative medicine protocols.
TAFA2 is a member of the TAFA gene family comprising
newly described chemoattractant neurokines with high expres-
sion in the central nervous system. The TAFA family is composed
of ﬁve highly homologous genes encoding small secreted pro-
teins that contain conserved cysteine residues at ﬁxed positions
[20]. The TAFA family is related to the chemokine, macrophage
inﬂammatory protein-1α (MIP1a/CCL3) that plays a role in
granulocyte recruitment to sites of neuroinﬂammation [24]. Sev-
eral C-C chemokines ligands, such as CCL3 [24], CCL4/MIP-β
[25], and CCL2/Monocyte chemoattractant protein-1 (MCP-1)
[26], are known for their modulatory functions on the migration
of endogenous or transplanted neural progenitors toward dam-
aged areas of the brain in ischemic stroke.
We observed that in vitro treatment of hMSC with TAFA2
resulted in enhanced trans-well migration as well as signiﬁ-
cant changes in cell morphology and cytoskeletal remodeling
as deﬁned by rearrangement of F-actin to form cell protru-
sions (lamellipodia) that are needed for cell movement [27].
Figure 2. TAFA2-induced lamellipodia formation and enhanced Rac1-p38 signaling in cultures of human skeletal (mesenchymal, stromal)
stem cells (hMSC). (A, B): Analysis of cell morphology of phalloidin-stained hMSC cultures using Operetta high-content imaging
system and cell area quantitation at single-cell level. Scale bar: 10 μm. Data represent mean  SEM from three independent experiments.
*, p ≤ .05, two-tailed unpaired Student t test. (C): Quantitation of Rac1 activity in hMSC cultures, 10, 15, 30, and 60 minutes after stimula-
tion with TAFA2 (10 μg/ml). (D): Quantitative reverse transcription polymerase chain reaction analysis of Rac1 expression in hMSC cul-
tures transfected with siRac1 or siCtrl. Data represent mean  SEM from three independent experiments. **, p ≤ .01, two-tailed
unpaired Student t test. (E): Quantitation of TAFA2-induced trans-well migration of hMSC transfected with siCtrl or siRac1. Data represent
mean  SEM from three independent experiments. *, p ≤ .05; **, p ≤ .01, two-tailed unpaired Student t test. (F): Western blot analysis
of P-p38, p38, P-Akt, Akt, P-ERK, ERK, and tubulin in lysates from hMSC cultures at different time points after stimulation with TAFA2
(10 μg/ml) or 10% fetal bovine serum. Data are representative of two independent experiments. (G, H): Quantitation of TAFA2-induced
trans-well migration in hMSC cultures pretreated with vehicle or p38 small molecule inhibitor (SB203580; 10 and 20 μM). Photomicro-
graphs show Hemacolor staining of the migrated hMSC. Scale bar: 50 μm. Data represent mean  SEM from three independent experi-
ments. **, p ≤ .01, two-tailed unpaired Student t test. Abbreviation: ARBU, arbitrary unit; siCtrl, control nontargeting small interfering
RNA; siRac1, small interfering RNA against Rac1.
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These responses are similar to changes in cell shape and
cytoskeleton induced by chemokines known to affect cell
motility [28]. Also, previous studies have demonstrated that
MSC can respond to chemoattractant proteins by reorganiz-
ing their actin cytoskeletons and become polarized in the
direction of the chemoattractant gradient [29, 30]. Indeed, a
disorganization of cytoskeletal F-actin has been associated
with impaired migration of not only MSC but also epidermal
cells and dendritic cells [31–33]. Formation of lamellipodia
and membrane polarization at the leading edge of a migrat-
ing cell enables directional cell movement [27]. TAFA2 treat-
ment of hMSC in two dimensional (2D) cultures resulted in
formation of lamellipodia in a nondirectional fashion. It is
plausible that restoration of Rac1 activity to initial levels at
60 minutes after treatment with TAFA2 represents a 2D-
culture phenomenon because of the absence of directional
migration. In addition, the chemoattractant effect of TAFA2
was associated with increased activity of the p38 signaling
which is known to mediate the migration of stem cells by
several chemotactic factors including: IL-33 [34], stromal cell-
derived factor 1 alpha (SDF-1α) [35, 36], and transforming
growth factor beta (TGF-β) [37]. It is plausible that p38 signal-
ing is induced after TAFA2 interaction with a cognate recep-
tor that remains to be determined.
We observed that TAFA2 is constitutively expressed in the
bone marrow by leukocyte and MSC, and its expression is
upregulated after in vitro osteoblast differentiation of MSC. In
contrast to several other factors, TAFA2 does not affect differ-
entiation capacity of the cells but enhances their proliferation,
which is consistent with a role in enhancing cell recruitment to
Figure 3. TAFA2-enhanced proliferation, but not differentiation, of human skeletal (mesenchymal, stromal) stem cells (hMSC). (A): Cell
number count in hMSC cultures at the baseline (day 0) or in the presence of vehicle or TAFA2 (10 μg/ml) for 6 days. Data represent
mean  SEM from three independent experiments. *, p ≤ .05, two-tailed unpaired Student t test. (B): Flow cytometry analysis of Ki67
levels in hMSC cultures in the presence of vehicle or TAFA2 (10 μg/ml). TAFA2-treated hMSC was also analyzed using isotype control anti-
body. (C, D): Quantitative reverse transcription polymerase chain reaction analysis of TAFA2 mRNA expression during osteoblast and adi-
pocyte differentiation of hMSC. Data represent mean  SEM from three independent experiments. **, p ≤ .01, two-tailed unpaired
Student t test. (E, F): Quantitation of ALP activity and ALP staining of osteogenic hMSC cultures 6 days after induction of differentiation.
Data represent mean  SEM from three independent experiments. (G, H): Analysis of mineralized matrix formation in osteogenic hMSC
cultures by quantitation of hydroxyapatite deposition using Osteoimage bone mineralization assay on day 15 of differentiation. Scale bar:
100 μm. Data represent mean  SEM from three independent experiments. **, p ≤ .01, two-tailed unpaired Student t test. (I, J): Quantiﬁ-
cation of mature adipocytes by measuring accumulated lipid droplets in the presence of adipocyte induction medium using Oil Red O
staining (day 15). Scale bar: 50 μm. Data represent mean  SEM from three independent experiments. **, p ≤ .01, two-tailed unpaired
Student t test. Abbreviations: ALP, alkaline phosphatase; CM, culture media; DAPI, 40,6-diamidino-2-phenylindole; HA, hydroxy apatite;
OIM, osteoblast induction media; AIM, adipocyte induction media.
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sites where bone formation is needed. In vivo, TAFA2 expres-
sion was upregulated in the callus area during the inﬂamma-
tory phase of fracture healing and also in the newly formed
chondrocytes. This expression pattern is similar to what has
been reported for other members of the C-C family. For exam-
ple, it has been reported that CCL3 and CCL4 (MIP1-β) are
expressed by the callus chondrocytes during fracture healing
[38]. The stimulating effects of TAFA2 on MSC in vitro transmi-
gration, the increased expression of TAFA2 during fracture
healing, and the absence of its direct effects of MSC differenti-
ation suggest a possible role for in vivo chemotactic effects on
MSC during fracture healing. Previous studies have shown that
the number of osteoprogenitor cells in systemic circulation is
increased after bone fracture [39]. It is thus plausible that the
Figure 4. TAFA2 levels are regulated during the process of fracture healing. (A): Immunohistochemical analysis of TAFA2 protein expres-
sion in a fractured femur, 48 hours after induction of fracture. Scale bar: 1 mm. (B): Analysis of TAFA2 immunoreactivity at the fracture
site (boxed area from A) at different time points (2, 24, and 48 hours, 4 days, and 1 week) after induction of femoral fracture (upper
panel) and nonfractured femur (lower panel). Scale bar: 100 μm. (C): Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) analysis of TAFA2 mRNA expression in nonfractured and fractured mouse femur at different time points after fracture induction
(2 hours, day 1, day 4, and day 14). (D): Flow cytometry analysis of TAFA2 protein expression in bone marrow cells obtained from frac-
tured femur at different time points. Data represent MFI  SEM from three independent experiments. **, p ≤ .01; two-tailed unpaired
Student t test. (E): qRT-PCR analysis of IL-1β mRNA expression in mouse femur before fracture and at different time points after fracture
induction (2 hours, day 1, day 4, and day 14). (F): qRT-PCR analysis of TAFA2 mRNA expression in human skeletal (mesenchymal, stromal)
stem cell (hMSC) cultures in the presence of different doses of IL-1β (1, 10, and 50 ng/ml) for 48 hours. Data represent three independent
experiments  SEM; **, p ≤ .01, two-tailed paired Student t test. (G, H): Western blot analysis and quantiﬁcation of TAFA2 protein levels
in hMSC cultures in the presence of different doses of IL-1β. Data represent mean  SEM from four independent experiments. *, p ≤ .05,
two-tailed unpaired Student t test. (I, J): Flow cytometry analysis of TAFA2 protein expression and percentage of leukocytes (CD45+),
monocytes (CD14+), T cells (CD3+), and B cells (CD19+) at 1 and 3 days postfracture. Data are obtained from pooled bone marrow cells iso-
lated from fractured femurs of three mice. (K): Enzyme-linked immunosorbent assay measurement of TAFA2 levels in consecutive serum
samples from patients with hip fracture. **, p ≤ .01, two-tailed paired Student t test. (L): Proposed model for role of TAFA2 in recruiting
MSC to the site of fracture. Abbreviations: IL, interleukins; MFI, mean ﬂuorescence intensity; MSC, skeletal (mesenchymal) stem cell.
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presence of high levels of TAFA2 inside the bone fracture
microenvironment during the inﬂammatory phase of fracture
healing results in recruitment of osteoprogenitor cells needed
for subsequent bone formation (Fig. 4L). Future studies are
needed to determine whether local expression of TAFA2 at the
fracture site could be used to increase recruitment of osteo-
progenitors and to enhance the fracture healing.
CONCLUSION
We demonstrate that during the inﬂammatory phase of frac-
ture healing, TAFA2 levels are increased at the site of fracture
that leads to recruitment of osteogenic cells to the fracture
site through activation of Rac1-p38 signaling.
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